Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same journal

Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer.

Molecular diagnosis & therapy·2026
Same journal

Genetics of Cerebrotendinous Xanthomatosis.

Molecular diagnosis & therapy·2026
Same journal

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026
Same journal

LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.

Molecular diagnosis & therapy·2026
Same journal

Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.

Molecular diagnosis & therapy·2026
Same journal

Real-Time Detection of Colorectal Cancer Using Topical Application of a pH-Activatable Fluorophore.

Molecular diagnosis & therapy·2026
See all related articles
  1. Home
  3. Tividenofusp Alfa: First Approval.
  1. Home
  3. Tividenofusp Alfa: First Approval.

Related Experiment Videos

Tividenofusp Alfa: First Approval.

Matt Shirley1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular Diagnosis & Therapy
|June 18, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Tividenofusp alfa, a novel enzyme replacement therapy, shows promise for treating Hunter syndrome (MPS II). Its development led to accelerated US approval for neurologic manifestations in pediatric patients.

Related Experiment Videos

Area of Science:

  • Biotechnology and Enzyme Replacement Therapy
  • Lysosomal Storage Diseases
  • Neurology

Background:

  • Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare X-linked recessive lysosomal storage disease.
  • It results from iduronate-2-sulfatase deficiency, leading to glycosaminoglycan accumulation.
  • Current treatments are limited, especially for central nervous system manifestations.

Purpose of the Study:

  • To summarize the development milestones of tividenofusp alfa for MPS II.
  • To highlight the clinical data supporting its accelerated approval.
  • To provide an overview of its novel mechanism for CNS penetration.

Main Methods:

  • Development of tividenofusp alfa, an enzyme fused to a transferrin receptor-binding Fc domain.
  • Phase I/II clinical trial evaluating safety, tolerability, and efficacy.
  • Assessment of cerebrospinal fluid heparan sulphate levels as a biomarker.

    • Main Results:

    • Tividenofusp alfa demonstrated reduction in cerebrospinal fluid heparan sulphate levels in MPS II patients.
    • Accelerated approval granted in the USA in March 2026 for neurologic manifestations.
    • Priority Medicine designation received from the European Medicines Agency.

    Conclusions:

    • Tividenofusp alfa represents a significant advancement in MPS II treatment, particularly for neurologic aspects.
    • Its brain-penetrant design facilitates enzyme delivery to both CNS and peripheral tissues.
    • Continued approval is contingent on confirmatory trial results verifying clinical benefit.